Singapore, 23 July 2020: Independent pharmaceutical company Specialised Therapeutics Asia (ST Asia) has appointed two senior executives to its Singapore team, as it drives commercialisation of new oncology products in the region.
Dr Bhuvana Ramaswamy will commence as Senior Medical Advisor for South East Asia in October, bringing extensive oncology, scientific and pharmaceutical industry expertise to the role.
Dr Ramaswamy will be joined by new Senior Business Manager Mr Kurt Sim, who has an extensive background commercialising oncology and haematology products throughout South East Asia, along with broad regulatory and market access expertise.
STA Chief Executive Officer Mr Carlo Montagner said these appointments would bolster the company’s regional presence and were further evidence of its commitment to providing new therapies to patients throughout Australia, New Zealand and across South East Asia.
“These are complex regions with nuanced regulatory, medical and commercial requirements,” Mr Montagner said.
“Our regulatory team has recently achieved several new oncology product approvals in these complex regions, including Singapore, Malaysia and Brunei, with more approvals expected in coming months.
“We are building on these tremendous efforts and ensuring we have the relevant scientific and commercial personnel, with the capability to work closely with clinicians and deliver new approved therapies and technologies to South East Asian patients as rapidly as possible. Appointing senior people with intimate knowledge of these regions is imperative to executing this plan.
“We are confident these new executive appointments will enable STA to expeditiously execute its growth strategy and ensure patients have access to new therapies and technologies at the earliest opportunity.”
Originally from India, Dr Bhuvana Ramaswamy moved to Singapore 20 years ago, and has been heavily involved in a number of clinical trials at Singapore’s National Cancer Centre. She has held senior medical and scientific roles in the global pharmaceutical industry, including roles at Ipsen and Bristol Myer Squibb (BMS), developing relationships with oncologists across Singapore and Malaysia.
Mr Sim has acquired valuable commercial expertise in previous roles throughout the Asia Pacific, as a Regional Business Development Manager at Ipsen and in other commercial and sales management roles at global pharmaceutical companies including Roche, Wyeth and Mundipharma.
His valuable oncology and haematology networks in Singapore, Malaysia and Brunei are supported by extensive experience preparing contract agreements, regulatory access and named patient programs in numerous countries across the region.
Dr Ramaswamy and Mr Sim will be based at ST Asia’s Singapore headquarters.
Headquartered in Singapore, Specialised Therapeutics Asia Pte Ltd (STA) is an international biopharmaceutical company established to provide new therapies and technologies to patients throughout South East Asia, as well as in Australia and New Zealand. STA and its regional affiliates collaborate with leading global pharmaceutical and diagnostic companies to bring novel, innovative and life-changing healthcare solutions to patients affected by a range of diseases. Its mission is to provide therapies where there is an unmet need. The company’s broad therapeutic portfolio currently includes novel agents in oncology, haematology, neurology, ophthalmology and supportive care.
Additional information can be found at www.stbiopharma.com
Emma Power, Corporate Affairs and Communications Manager, Specialised Therapeutics Asia +61 419 149 525 or firstname.lastname@example.org